Navigation Links
Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer
Date:6/3/2010

ma‚ and infectious disease. While Vice President of Clinical Research at CV Therapeutics‚ Dr. Hislop was the development leader for the company's first product, Ranexa® (ranolazine), and championed the NDA efforts for this cardiovascular compound. Prior to CVT‚ Dr. Hislop spent seven years at Proctor and Gamble as the worldwide clinical development manager for P&G's osteoporosis drug, Actonel® (risedronate sodium). He also worked at Eli Lilly and Company in the UK as a medical advisor for the endocrinology group. Dr. Hislop has a B.Sc. from University of Surrey in Medical Biochemistry and an M.D., B.S. from the University of London.

Dr. Pennington has over 25 years of experience in the pharmaceutical industry during which he was responsible for 14 NDA and BLA approvals in the United States and 10 product approvals in countries outside the US. He joined Anthera in 2007 from CoTherix, Inc. where he served as Executive Vice President and Chief Medical Officer of a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiovascular diseases. Previously, he was Executive Vice President, Medical and Scientific Affairs and Chief Medical Officer of InterMune, Inc., a publicly-traded biopharmaceutical company focused on the development, applied research and marketing of life-saving therapies for pulmonary and hepatic diseases, and also served as Vice President of Biological and Biotechnology Clinical Development of Bayer Corporation for 11 years. Prior to entering the pharmaceutical industry, Dr. Pennington also has years of experience in academia at Harvard Medical School and the University of California, San Francisco. He attended the University of Oregon School o
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
2. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
3. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
4. Anthera Presents Data on Varespladib at ATVB Meeting
5. Anthera Pharmaceuticals Forms Scientific Advisory Board
6. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
7. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
8. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
9. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
10. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
11. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... N.J. , April 24, 2015  Navitas Life Sciences ... as Head of Clinical and Regulatory Services. Shalabh is ... been a co-founder and CEO of Kinapse, as well as ... Logo - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... Jim Tizzard commented "I am delighted to welcome Shalabh ...
(Date:4/23/2015)... 23, 2015 The Thomas Brain ... conduct a groundbreaking pilot study to see if ... in as little as three to six months. ... and nutritional medicine—will aggressively target and simultaneously treat ... our aging brain. These include oxidative stress, neuroinflammation, ...
(Date:4/23/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company serving the pharmaceutical, biotechnology and medical device industries, ... the United States , today announced ... quarter of 2015 after the New York Stock Exchange ... Thursday morning, May 14, 2015 Shanghai time). The earnings ...
(Date:4/23/2015)... April 23, 2015 Glemser ... the first EMC® Enterprise Content Division (ECD) Certified ... EMC Documentum® for Life Sciences Solution Suite ... knowledge and capabilities to provide life sciences companies ... , The EMC Documentum Solution Suite offers ...
Breaking Biology Technology:Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Glemser Earns Accreditation for Life Sciences Solution Suite 2
... Omeros Corporation (NASDAQ: OMER ), ... and commercializing products targeting inflammation, coagulopathies and disorders ... Gregory A. Demopulos, M.D., chairman and chief executive ... and Renshaw 13th Annual Healthcare Conference taking place ...
... , Gains US Patent Protection for Proprietary AAV Intellectual ... leader in the field of human gene therapy, today ... agreement with the US National Institutes of Health (NIH) ... therapy vectors for liver and brain indications. This agreement ...
... This September, during Prostate Cancer Awareness Month , ... method that may change the face of prostate ... and one Boston hospital, analyzed by the National Cancer Institute, ... Dr. David Samadi, Vice Chairman, Department of Urology, and ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health 2Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health 3More Precise Prostate Cancer Screening on Horizon 2More Precise Prostate Cancer Screening on Horizon 3
(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... New research from The University of Western Ontario leads ... the Arctic Circle during the Pleistocene Epoch (approx. 150,000 ... three years later than modern day African elephants due ... nursing pattern could have contributed to the prehistoric elephant,s ...
... 21, 2010 Reportlinker.com announces that a new market ... Indian Biometric Market http://www.reportlinker.com/p0351944/Indian-Biometric-Market.html ... fastest emerging technology in the Indian Securities & Identification ... many conventional methods of Identity & Security checks like, ...
... Miscanthus x giganteus is the forerunner in the ... researchers believe "putting all their eggs in one basket" could ... recently reported the first natural occurrence in several decades of ... M. x giganteus is the only variety available, ...
Cached Biology News:Being good moms couldn't save the woolly mammoth 2New Miscanthus hybrid discovery in Japan could open doors for biofuel industry 2New Miscanthus hybrid discovery in Japan could open doors for biofuel industry 3
G-protein coupled purinergic receptor P2Y8...
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Biology Products: